Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
Expanding the approval to pediatric patients is expected to improve the diagnostic accuracy of echocardiograms. The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A ...
Findings from pediatric trials showed left ventricular opacification with Definity was successful and provided important information to guide patient management. The Food and Drug Administration (FDA) ...
GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Lantheus Holdings, Inc. LNTH recently announced that the FDA has approved the supplemental new drug application for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound-enhancing agent for use in ...
Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...
The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results